#1 Clinical Trials Search in Europe

Ocrelizumab

Ocrelizumab, marketed as Ocrevus, is a promising medication being studied extensively in clinical trials for the treatment of multiple sclerosis (MS). These trials aim to evaluate its efficacy, safety, and long-term effects in patients with relapsing-remitting MS and other forms of the disease. Researchers are investigating various aspects, including its impact on disease progression, patient satisfaction, and effects on the immune system.

Table of Contents

What is Ocrelizumab?

Ocrelizumab, also known by its brand name Ocrevus, is a medication used to treat certain types of multiple sclerosis (MS)[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to target specific cells in the body[2].

What Conditions Does Ocrelizumab Treat?

Ocrelizumab is primarily used to treat two forms of multiple sclerosis:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery[3].
  • Primary Progressive Multiple Sclerosis (PPMS): This is a less common form of MS where symptoms steadily worsen over time without periods of recovery[1].

Additionally, some studies are investigating its use in patients with Clinically Isolated Syndrome (CIS), which is the first episode of neurological symptoms that could potentially develop into MS[4].

How Does Ocrelizumab Work?

Ocrelizumab works by targeting and depleting a specific type of immune cell called B cells. These cells are believed to play a crucial role in the progression of MS[5]. By reducing the number of B cells, ocrelizumab helps to:

  • Decrease inflammation in the nervous system
  • Slow down the progression of disability
  • Reduce the frequency of relapses in people with RRMS

The medication specifically targets B cells that have a protein called CD20 on their surface. This targeted approach helps to preserve other important immune cells, allowing the body to continue fighting infections[3].

How is Ocrelizumab Administered?

Ocrelizumab is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The typical dosing schedule is as follows:

  • Initial treatment: Two 300 mg infusions given two weeks apart
  • Subsequent treatments: A single 600 mg infusion every 24 weeks (about every 6 months)[1]

Each infusion usually takes several hours to complete. Your healthcare provider will monitor you during and after the infusion for any potential side effects[6].

Effectiveness of Ocrelizumab

Clinical trials have shown that ocrelizumab can be highly effective in treating MS. Some key benefits include:

  • Reducing the frequency of relapses in RRMS
  • Slowing the progression of disability in both RRMS and PPMS
  • Reducing the number of new or enlarging brain lesions seen on MRI scans[1]

One study found that ocrelizumab could potentially delay the time it takes for 50% of patients to need a wheelchair by about 7 years compared to placebo treatment[1]. However, it’s important to note that the effectiveness can vary from person to person.

Potential Side Effects

Like all medications, ocrelizumab can cause side effects. Some of the most common include:

  • Infusion-related reactions: These can occur during or shortly after receiving the infusion and may include itching, rash, fever, or difficulty breathing.
  • Increased risk of infections: Because ocrelizumab affects your immune system, it may increase your risk of getting certain infections.
  • Headache
  • Upper respiratory tract infections[6]

Your healthcare provider will monitor you closely for these and other potential side effects.

Special Considerations

There are some special considerations to keep in mind when taking ocrelizumab:

  • Vaccinations: You should complete any required vaccinations at least 6 weeks before starting ocrelizumab.
  • Pregnancy and breastfeeding: The effects of ocrelizumab on pregnancy and breastfeeding are not fully known. If you’re pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor[4].
  • Regular monitoring: Your doctor will likely want to monitor your blood cell counts and perform regular MRI scans to check the effectiveness of the treatment[3].

Ongoing Research

Researchers continue to study ocrelizumab to better understand its long-term effects and potential uses. Some areas of ongoing research include:

  • The effects of ocrelizumab on B cells in lymph nodes[7]
  • The presence of ocrelizumab in breast milk and its potential effects on infants[8]
  • The impact of ocrelizumab on different types of immune cells and how this relates to its effectiveness in treating MS[9]
  • Personalized dosing schedules based on individual B cell levels[3]

These ongoing studies aim to improve our understanding of ocrelizumab and potentially optimize its use in treating MS.

Aspect Details
Primary Focus Efficacy and safety of ocrelizumab in treating multiple sclerosis
Key Outcomes Relapse prevention, disability progression, MRI lesions, quality of life
Administration Intravenous infusion, typically 600 mg every 6 months
Special Studies B-cell tailored dosing, effects on breastfeeding, immune cell changes
Safety Monitoring Infusion reactions, infections, long-term immune system effects
Patient Populations Relapsing-remitting MS, clinically isolated syndrome, lactating women
Biomarkers B-cell levels, neurofilament light chain, MRI changes

FAQ

  • What is ocrelizumab and how does it work? Ocrelizumab is a medication used to treat multiple sclerosis. It works by targeting and depleting B cells, a type of immune cell thought to play a role in MS. By reducing these cells, ocrelizumab aims to slow down the progression of the disease.
  • How is ocrelizumab administered? Ocrelizumab is typically administered as an intravenous (IV) infusion. The initial dose is often given as two 300 mg infusions separated by two weeks, followed by 600 mg infusions every six months. Some trials are also studying subcutaneous injections.
  • What are the main outcomes being studied in ocrelizumab clinical trials? Clinical trials are evaluating various outcomes, including the drug's ability to prevent relapses, slow disability progression, reduce brain lesions seen on MRI, and improve patients' quality of life. Researchers are also studying its long-term safety and effects on specific immune cells.
  • Are there any studies looking at ocrelizumab in special populations? Yes, some studies are focusing on specific groups, such as lactating women with MS. These trials aim to understand how the drug is transferred into breast milk and its potential effects on infants.
  • What are some potential side effects of ocrelizumab being monitored in trials? Clinical trials are monitoring for various side effects, including infusion-related reactions, infections, and changes in immune cell levels. Long-term safety is a key focus, as well as any potential impact on infant development in studies involving breastfeeding mothers.

Ongoing Clinical Trials on Ocrelizumab

  • A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Hungary Italy Poland Portugal +1

  • Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +4

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria France Germany

  • Study on Monitoring Ocrelizumab Levels for Personalized Treatment in Patients with Relapsing-Remitting and Primary Progressive Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Norway Sweden

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark France +9

Glossary

  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Relapsing-Remitting MS (RRMS): The most common form of MS, characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Ocrelizumab: A medication used to treat MS that works by targeting and depleting B cells in the immune system.
  • B cells: A type of white blood cell of the immune system that plays a role in the MS disease process.
  • Infusion: A method of delivering medication directly into a vein over a period of time.
  • MRI: Magnetic Resonance Imaging, a technique used to create detailed images of the brain and spinal cord to detect MS lesions.
  • T cells: Another type of white blood cell important in the immune system and MS.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in MS and monitoring changes over time.
  • Neurofilament light chain (NfL): A protein released when nerve cells are damaged, used as a biomarker in MS.
  • Clinically Isolated Syndrome (CIS): A first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system, which may or may not develop into MS.

References

  1. https://clinicaltrials.gov/study/NCT05210621
  2. https://clinicaltrials.gov/study/NCT00808210
  3. https://clinicaltrials.gov/study/NCT05296161
  4. https://clinicaltrials.gov/study/NCT04998851
  5. https://clinicaltrials.gov/study/NCT04261790
  6. https://clinicaltrials.gov/study/NCT02637856
  7. https://clinicaltrials.gov/study/NCT06495593
  8. https://clinicaltrials.gov/study/NCT04387110
  9. https://clinicaltrials.gov/study/NCT04459988